Key result
Left atrial BNP expression remains stable across CHF phenotypes and does not correlate with plasma NT-proBNP.
Observational (n=75)
Left atrial myocardial BNP expression reaches a plateau in coronary artery disease patients even before clinical heart failure manifests and does not correlate with rising plasma NT-proBNP levels as LVEF declines, suggesting the ventricles drive systemic NT-proBNP elevation in manifest heart failure.
Answers are grounded in this paper and cite their sources.
Challenges assumption of atrial BNP driving NT-proBNP rise in CHF; leaves open ventricular sources for prospective validation.
Background. Chronic heart failure (CHF) remains a leading cause of hospitalizations and mortality. Measuring blood NT-proBNP concentration is recognized as the “gold standard” for CHF diagnosis. Normally, the atria are considered the primary source of atrial natriuretic peptide (ANP); however, their true contribution to systemic hyperpeptidemia due to B-type natriuretic peptide (BNP) during the progression of various CHF phenotypes and the reduction of left ventricular ejection fraction (LVEF) remains insufficiently studied. Objective. To compare B-type natriuretic peptide (BNP) expression in the left atrial (LA) myocardium across different CHF phenotypes and evaluate its association with plasma level of NT-proBNP. Materials and Methods. In a prospective clinical and morphological study, 75 patients with coronary artery disease after elective coronary artery bypass grafting were examined: comparison group (without clinically manifest CHF, n = 17), CHF with preserved EF (≥ 50 %, n = 20), and a cohort of CHF with reduced/mildly reduced EF (< 50 %, n = 38). BNP expression in LA appendage biopsies was assessed immunohistochemically (percentage of positive cells, H-score). Plasma NT-proBNP levels were determined by ELISA. Results. Plasma NT-proBNP concentrations increased proportionally to the decrease in LVEF: 296.6 pg/mL in the comparison group, 678.8 pg/mL at EF ≥ 50 %, and 1033.2 pg/mL at EF < 50 % (p < 0.001). Meanwhile, tissue BNP expression in the LA remained stable: the percentage of positive cells was 41.5–42.7 %, and the H-score was 64.4–74.3 points (p = 0.139). No significant correlation was found between the LA tissue H-score and plasma NT-proBNP (r = –0.084; p = 0.455). Conclusion. BNP expression in the LA myocardium reaches a functional “atrial plateau” already in coronary artery disease patients without clinical signs of CHF. The lack of increased BNP production in the atria despite the decrease in LVEF indirectly indicates that the ventricular myocardium is the dominant driver of systemic hyperpeptidemia in the manifest stages of the disease.
No takes yet. Share an insight, caveat, or question.
Ирекович et al. (2026) conducted an observational in Chronic heart failure and coronary artery disease (n=75). Chronic heart failure phenotypes (preserved EF >=50% and reduced/mildly reduced EF <50%) vs. Coronary artery disease without clinically manifest CHF was evaluated on B-type natriuretic peptide (BNP) expression in the left atrial myocardium (percentage of positive cells and H-score) and its association with plasma NT-proBNP levels (r -0.084, p=0.139). Left atrial BNP expression remained stable across CHF phenotypes and did not correlate with rising plasma NT-proBNP.
Synapse has enriched 10 related papers. Consider them for comparative context: